Objective: To systematically review the published academic literature on the cost of chronic ulcers. Methods: A literature search was conducted in MEDLINE, EMBASE, HealthSTAR, Econlit and CINAHL up to 12 May 2016 to identify potential studies for review. Cost search terms were based on validated algorithms. Clinical search terms were based on recent Cochrane reviews of interventions for chronic ulcers. Titles and abstracts were screened by two reviewers to determine eligibility for full text review. Study characteristics were summarised. The quality of reporting was evaluated using a modified cost-of-illness checklist. Mean costs were adjusted and inflated to 2015 $US and presented for different durations and perspectives. Results: Of 2267 studies identified, 36 were eligible and included in the systematic review. Most studies presented results from the healthcare public payer or hospital perspective. Many studies included hospital costs in the analysis and only reported total costs without presenting condition-specific attributable costs. The mean cost of chronic ulcers ranged from $1000 per year for patient out of pocket costs to $30,000 per episode from the health-care public payer perspective. Mean one year cost from a health-care public payer perspective was $44,200 for diabetic foot ulcer (DFU), $15,400 for pressure ulcer (PU) and $11,000 for leg ulcer (LU).
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Conclusions:
There was large variability in study methods, perspectives, cost components and jurisdictions, making interpretation of costs difficult. Nevertheless, it appears that the cost for the treatment of chronic ulcers is substantial and greater attention needs to be made for preventive measures.
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The authors have nothing to declare. C hronic ulcers do not follow the typical healing process of inflammation, proliferation and remodelling 1 in an orderly or timely fashion 2 and thereby prolong the healing time. Chronic ulcers are observed in a variety of health-care settings. Although they may include arterial ulcers and chronic surgical and traumatic wounds, the focus of this article will be on diabetic foot ulcers (DFUs), pressure ulcers (PUs) and leg ulcers (LUs). The prevalence of DFU has been observed to be 8 % in the acute care setting 3 and between 8-17 % in the community setting. 4 PU prevalence is reported to be between 12-27 % in the acute care setting, [5] [6] [7] 15 % in community care, 8 9-43 % in long-term residential care, 9 29-32 % in long-term acute care facilities 10 and 16-19 % in rehabilitation facilities. 10 Of the PUs reported in an acute care setting, almost 4/5 are hospital-acquired. 11 For LUs, the prevalence has been calculated to be approximately 0.045-0.56 %. 12, 13 Chronic ulcers will continue to be a growing cost-of-illness • pressure ulcer • diabetic foot • leg ulcer • health care costs • health services research concern as the population ages and more people will be at risk for developing these conditions. 14, 15 This has resulted in one researcher considering chronic ulcers a 'major and snowballing threat to public health and the economy'. 16 Compounding the issue of high prevalence of chronic ulcers is the additional health-care resources required to treat this condition. Foot ulcers require numerous hospital and physician visits. 17 PUs were observed to increase length of stay by an average of 4 days. 18 The standard of care for chronic ulcers is debridement, infection control, moisture balance 19, 20 and wound cleansing, 21,22 with pressure offloading for DFUs and PUs, 19, 22 and compression therapy for LUs. 20 This requires a significant amount of health professionals' time, for example, in the acute care setting, approximately 45 % of patients with a wound require one or more dressings per day. 11 With an average dressing time of 10.5 minutes (range: 8.1-17.4 minutes), 11 the total time spent on dressing changes alone is substantial.
If we combine the high prevalence of chronic ulcers with the resource intensity of treatment, the economic burden to the health-care system is expected to be high. The extent of the economic burden of chronic ulcers has not been evaluated systematically. We conducted a systematic review of the literature on the cost-of-illness of chronic ulcers in order to understand the burden of illness associated with this condition.
The specific aim of this study was to review the published literature on the economic cost of chronic ulcers to determine the mean cost per ulcer case.
Methods
We conducted a search for chronic ulcer cost-of-illness studies using MEDLINE, EMBASE, HealthSTAR, EconLit and CINAHL. Costing search terms were based on the algorithm determined by Wilczynski and colleagues identified as having the optimal sensitivity (95 %) and specificity (95.6 %) for identifying cost studies. 23 The search algorithm was an explosion of the Medical Subject Heading term 'costs and cost analysis' and 'costs' or 'cost' in the title or abstract. Our EMBASE cost search strategy was based on the algorithm with optimal sensitivity (98.4 %) and specificity (97.1 %) as determined by McKinlay and colleagues. 24 The algorithm included a free text search of the term 'cost', 'costs' in the title or abstract or 'health care cost' as the subject heading. No studies have tested the performance of costing algorithms for CINAHL, HealthSTAR or EconLit. Thus, the search strategy for these databases was based on the MEDLINE search and leveraged the prior strategy used. For chronic ulcers, search terms were based on recent Cochrane reviews. [25] [26] [27] A list of the clinical terms included in the search strategies is presented in Table 1 . Limits were placed on all searches to narrow the retrieved studies in an attempt to exclude case reports, clinical trials, comments, letters, editorials and reviews. All studies were in humans and in the English language. Studies were also limited to articles published between 1994-2016. Earlier studies would have been less relevant for our review given the increase in health-care expenditures that have occurred over time and different treatment protocols and practices that have developed. The full search for all databases is presented in appendix a1-a4. All database searches were completed by 12 May 2016.
Exclusion criteria
The titles and abstracts of all studies were retrieved and reviewed by two authors to exclude studies that were not chronic ulcer and cost-of-illness related. Articles were excluded if cost-of-illness was not the primary or secondary outcome, or if they were economic evaluations that reported costs in a chronic ulcer population administered a specific intervention or clinical trial because the purpose of this systematic review was to evaluate costs for the chronic ulcer population in general and not for a specific intervention. The reference lists of included studies were reviewed for additional studies not captured in the database searches.
Review of the study characteristics The following characteristics of included studies were collected and summarised in detail: ulcer type, country of origin, study perspective, health-care setting that patient cohort originated from, data source and whether it was an incident or prevalent population, health-care cost components incorporated into the cost calculation, whether top-down or bottom-up costing methods were used and total costs were reported (total cost, disease specific cost or net cost).
Quality of reporting in cost-of-illness studies
There is currently no general consensus on the recommended tool or checklist to assess the quality of cost-of-illness studies. A critical evaluation of cost-ofillness studies by Larg and Moss 28 was selected as a framework for evaluating the quality of the methods of the articles extracted. This checklist consisted of 29 questions related to the 'analytical framework', 'methodology and data' and 'analysis and reporting' and was developed to assess the overall quality of costof-illness studies. Most of these questions require the subjective interpretation of the reviewer. Thus, this checklist was adapted for our study by selecting a subset of questions and reworded to evaluate the completeness of study reporting to allow the authors to analyse the results. Cohen's kappa coefficient was measured to calculate the agreement between the two reviewers for each individual question on the reporting checklist.
Calculating the cost of chronic ulcers
Results were converted to US currency using purchasing power parity rates 29 published by the Organisation for Economic Co-operation and Development (OECD).
Where studies originated from countries that did not report to the OECD, official exchange rates published by the World Bank were used. Results were then inflated to 2015 year dollars using the US consumer price index for health care. 30 Study results reported as costs per week or month were translated to a cost per episode by converting the weekly or monthly cost by the mean number of days per episode. Studies have observed mean length per episode of 90 days for DFU 31 to 94 days for PU. 32 For our analyses, 90 days was chosen for the episode length of DFUs, PUs and VLUs.
Results were presented as the mean overall cost of chronic ulcer per person for all chronic ulcers, and stratified into three groups: DFU, PU and VLU. Studies that reported mean disease specific cost or mean net cost were identified and aggregated when possible. To provide a cost comparison between chronic ulcer types, an attempt was made to find studies with comparable perspective and follow-up duration for all three chronic ulcer types. Finally, individuals with certain medical conditions, such as spinal cord injury and obesity, have higher prevalence for chronic ulcers and thus a complex disease profile. These cohorts were examined separately.
Terminology A study cohort was considered incident if participants were enrolled at the beginning of the chronic ulcer episode. The cohort was considered prevalent if participants were collected during their chronic ulcer episode, as is common in a cross-sectional study. In studies that used bottom-up costing methods, healthcare resources or services were tallied and multiplied by the respective unit cost by the study authors. In topdown methods, the total costs of a health-care setting (i.e. hospital or long-term care facility) or service is known for all patients regardless of disease. The proportion of the total costs attributed to chronic ulcer patients was determined by examining the proportion of the total cases that were related to chronic ulcers, or by assigning a weight to each case. More detailed explanations of these cost-of-illness methods have been presented previously. 33, 34 Results were considered disease-specific cost if chronic-ulcer related cost components were identified a priori and results were reported separately from the total costs. Net costs were considered if authors calculated the difference in costs between a chronic ulcer cohort and a matched nonchronic ulcer cohort.
Results
A total of 2267 unique articles were identified (Fig 1) . Both reviewers agreed on the inclusion of 95 articles, with initial disagreement on the inclusion of 29 other papers. After a follow-up discussion, the disagreements were resolved and none of the 29 papers were included in the full-text review. The Cohen's kappa coefficient for inter-rater agreement was 0.88. After a review of the full-text, a total of 61 articles were excluded, with the remaining 34 included for synthesis (Fig 1) . We identified two additional studies in the reference list of the articles that were reviewed in full-text which were included in the synthesis. A summary of the studies included in the systematic review is presented in Table 2 . Presentation of the study characteristics stratified by ulcer type is presented in the appendix Table a8 . Given the large number of different perspectives and cost duration that the cost-of-illness study results were based on the overall costs, disease specific costs and net costs were presented with the most common durations (an ulcer episode, 1 year and hospital episode) and the most common costing perspectives (e.g. public payer, hospital).
Quality of reporting
Of a total of 506 cost-of-illness reporting checklist entries, there was disagreement in 11. The Cohen's kappa coefficient for inter-rater agreement was 0.83. After a discussion between reviewers, all discrepancies were resolved. The results of the checklist on the completeness of reporting showed that the studies included were generally reported completely (appendix a6-a7). The exception was the year which the cost results represent, with only 26 of the studies (72 %) reporting that data.
Overall costs
There were five studies which focussed on a specific chronic ulcer severity, or presented costs stratified by ulcer severity but did not report total costs. Weighted costs were calculated from these studies if the number or percentage of patients in each severity category was presented. Weighted mean costs were calculated for two studies, 35, 36 and two other studies 32, 37 were excluded because they did not present the number or percentage in each severity category. The last study only presented a PU cohort with the highest severity 38 and was excluded as well. This resulted in 33 remaining studies. The total mean cost of chronic ulcers not stratified by chronic ulcer type for the most common duration and cost perspectives is presented in Table 3 .
Comprehensive results are presented in the appendix 
Disease-specific costs
Of the 33 studies that presented general chronic ulcer costs (not specific to an ulcer severity), a total of seven studies reported chronic ulcer disease specific costs. 31, [39] [40] [41] [42] [43] [44] Of these three studies examined DFUs, 31, 39, 40 three looked at LUs 41, 42, 44 and one reported PUs. 43 The mean disease specific cost per episode for DFU from a health-care public payer perspective is $10,472 while the one year cost for LU is $18,444 from a health-care public payer perspective and $15,326 from a societal perspective. [39] [40] [41] [42] One additional study on DFUs observed a cost per episode of $21,600 from a Managed Care Organization perspective. 31 Another additional study examined leg ulcer costs and observed one year cost of $180 from a primary care clinic perspective. 44 Xakellis and colleagues evaluated the cost of PUs from a long-term care perspective and observed a cost of $9100 per episode. 43 Net costs Net costs were calculated by five studies; 18,45-48 two for DFUs, two for PUs and one for LUs. The mean net one year cost, from the perspective of the health-care public payer, is $5899 for DFU and $2811 for LU. Net cost for a PU hospital episode is $1151 from a health-care public payer perspective and $31,344 from a hospital perspective. In addition, Ramsey and colleagues calculated net cost for DFU (first year net: $43,400, second year net: $6,400) from a US third party payer perspective. 45 Rice and others calculated net cost of DFU (1 year net: $10,700 (±$38,000)) and LU (1 year net: $3,300 (±$17,400)) from a third party payer perspective. 46 Disease subgroups Chronic ulcers in a spinal cord injured population were examined in two studies. 49, 50 In the first, from a Canadian cohort, the results converted to a per episode mean cost were $13,400 (±$26,200) from a societal perspective. 49 In the second study, the cost-ofillness of PUs was calculated for spinal cord injured individuals being cared for by the Veterans Health Administration in the US. 50 The one year mean and median cost from the perspective of the public payer was $123,900 and $70,700. Health-care public payer Societal $13,393 Diabetic foot ulcer Pressure ulcer Hospital Health-care public payer $13,393 Diabetic foot ulcer Pressure ulcer
Cost drivers
To understand the health-care cost components that may be driving the cost of chronic ulcers, the cost of each health-care cost component reported for each study is presented in appendix Fig a6 stratified by ulcer type. This is by no means an in-depth analysis but a scan of the potential cost drivers, however, for all ulcer types, the main driver appears to be hospital costs.
Other potential cost drivers include physician costs for DFU, laboratory/diagnostic costs and home care costs for LUs and laboratory/diagnostic cost, other health practitioner costs and long-term care costs for PUs.
Discussion
Based on our systematic review, chronic ulcers are estimated to cost between $1000 for patient out of pocket per year and almost $35,000 per episode from the health-care public payer perspective. The wide variety of cost durations and perspectives presented in different studies made comparison of costs between chronic ulcer types challenging. One year hospital costs was the only cost duration and perspective with results for all chronic ulcer types. Comparing one year hospital costs, DFU had the highest costs followed by PU and LU being the least costly. Unfortunately, other comparable cost data for all three ulcer types were not available to see if this pattern held in other health-care settings.
The observation of variable results with large standard deviations suggests that the results presented should be interpreted with caution. There are several explanations for the large range of results observed in our review. Other researchers have suggested that the variability in cost-of-illness study results may be a result of: different selection of cohort, 51-54 different methods for cost calculation, [51] [52] [53] [55] [56] [57] differences in study design, 53, 58, 59 differences in coverage and services provided over time, 52, 54, 59 different data collection approaches 54, 58 and different cost components included. 54, 58 Despite the large variability in study methods, the reporting of methods and results were found to be adequate for data synthesis. Though the methods are not explicitly stated in most of the studies reviewed (incidence or prevalence method used, perspective used), there was enough information in the study text for a reviewer to determine what method should be used or how the results should be interpreted. The only exception would be the reporting year of reference for the costs presented. Since many studies collect data from multiple years, without a reference year reported, it was difficult to determine whether the costs have been inflated to current year costs or whether they represent the year in which the data was collected. Our results only evaluate the adequacy of the information presented to be able to interpret and compare results and should be considered a measure of minimum standards. It is by no means an evaluation of the methodological quality and rigor of the cost-of-illness studies. This would require a more comprehensive checklist that is beyond the scope of our analysis.
The characteristics of the chronic ulcer cost-of-illness studies in our review had similarities and differences compared with a review of US cost-of-illness studies for all diseases conducted by Clabaugh and colleagues. 60 In terms of similarities, the authors noted that many of their included studies also did not specify the study cost perspective. Most cost studies reviewed by these authors used a prevalence based approach (85 %), similar to our review of chronic ulcer studies (57 %). 60 Similar to our findings, most of the studies identified by Clabaugh and colleagues used administrative data sets. 60 Furthermore, the average number of health-care cost components per study observed was four, identical to our study.
There were also differences observed. Unlike our study where the most common perspective analysed was from the health-care public payer perspective, almost half of the studies included in Clabaugh's assessment were from the societal perspective (none from the health-care public payer perspective). 60 Also, more than half of the cost-of-illness studies reviewed by those authors included indirect costs, much more than our review (only 4 studies). The differences observed in Clabaugh and colleague's review may be a result of the differences in the inclusion criteria, which allows for all diseases, but limited to US studies that included at least two direct medical cost components.
Moving forward, future cost-of-illness studies for chronic ulcers should focus on identifying the disease specific or net cost of DFU, LU or PU. Similarly to the suggestions for improving cost-of-illness studies noted by Clabaugh and colleagues, 60 future chronic ulcer studies should attempt to incorporate a more comprehensive list of health-care cost components. This is especially important for PU studies which included a fewer average number of health-care cost components compared with DFUs and LUs studies (see appendix Table a6 ). This would provide a more accurate estimate of the cost of providing health-care for treating chronic ulcers. Furthermore, to compare the economic burden between chronic ulcers types, there should be an emphasis on using the same methods to determine costs.
We can go a long way in improving the methodology of cost-of-illness studies in general. One step forward is to standardise the methods 51 or identify best practice guidelines. The cost-of-illness reporting checklist developed for data synthesis in this systematic review is a step forward in improving the quality of these studies. A few additional suggestions for reporting that can facilitate the analysis and synthesis of future studies by researchers and health-care policy makers include:
• Reporting on the specific description of the population that is being analysed • Briefly describing the health-care funding structure of the jurisdiction that the study is based on • Strive to calculate a disease-specific cost or a net cost using a matched non-disease cohort. As a next step, cost-of-illness researchers, academics and health-care decision makers need to come together and produce guidelines for the development of cost-of-illness studies. This would result in more harmonious methods allowing health-care providers and decision makers to compare results between different disease areas and understand the relative economic impact of different diseases. The outcome of such efforts would be improved usefulness of cost-of-illness analysis.
Limitations
There are several limitations present in our systematic review. First of all, as noted earlier, the differences in methods, study perspectives, jurisdictions and cost components included in each study produce results with large variability. Second, almost half of the studies originated from the US. So the cost-of-care calculated in this review is heavily influenced by costs in the US. Third, more than half of the studies used administrative data as the main data source. Administrative data is primarily used for the planning and distribution of health-care services and may not collect all the resources consumed for the treatment of chronic ulcers. Fourth, though hospital costs were calculated in almost all of the studies reviewed, the other healthcare cost components were not as well represented in the studies, with pharmaceutical treatment being the second most common cost component calculated in half the studies. Fifth, we excluded cost-of-illness results from clinical trials and economic evaluations in an attempt to include only studies in a general chronic ulcer population. This may have excluded studies that had results representative of the general chronic ulcer population. Finally, only a small proportion of studies presented costs attributed to chronic ulcers with disease costs calculated in only 14 (39 %) and net costs only in 4 (11 %). Keeping these limitations in mind, this study was an attempt at estimating a cost for chronic ulcers and comparing the cost of different chronic ulcer types using all available data across all jurisdictions. This study also attempted to understand the characteristics of chronic ulcer cost-of-illness studies and to evaluate the quality of study reporting for the purposes of data synthesis.
Conclusions
There is a substantial economic burden for treating chronic ulcers. Standardising methods for cost-ofillness studies in general will allow researchers and policy makers to establish the importance of chronic ulcers in comparison with other diseases and may encourage greater research and policy initiatives for the prevention and treatment of chronic ulcers. JWC
